British Patient Capital

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

Founded in 2016, Form3 specializes in cloud-based payment processing services for regulated financial institutions. Its platform offers connectivity, payment processing, clearing, settlement, and a fully managed service model. Form3 serves a diverse range of clients including banks, non-bank financial institutions, and fintech companies.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Wagestream Ltd., founded in 2018 and headquartered in London, United Kingdom, develops a financial services application designed to enhance employee benefits and financial well-being. The platform allows employees to access their earned wages instantly, providing them with greater control over their pay schedules. This innovation aims to alleviate financial stress related to unexpected expenses by eliminating the need for advances, loans, and the burdens of high-interest credit or payday loans. Additionally, Wagestream offers various financial tools that help businesses support their employees in managing expenses, setting savings goals, and developing financial plans. By addressing these financial challenges, Wagestream seeks to reduce the poverty premium and prevent employees from falling into cycles of debt.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

CyberSmart Ltd., established in 2016 and headquartered in London, specializes in designing and developing automated compliance software platforms. The company offers a suite of products, including Cyber Essentials, Cyber Essentials Plus, GDPR Ready, CyberSmart Platform, and certOS, which help businesses identify, secure, and certify security incidents. Its cloud-based dashboard manages the compliance process, while desktop applications deployed across networks monitor compliance status and detect non-conformities. Additionally, CyberSmart provides ongoing protection through regular security checks and cyber insurance coverage, targeting small to medium-sized businesses seeking to mitigate cyber threats and navigate evolving regulations.

CloudNC is a London-based software company that develops autonomous manufacturing software to automate the programming of computer numerical control milling machines. It provides software and cloud-based services to design tooling paths and streamline CNC programming, enabling factories to produce precision metal components with minimal human intervention. The company also offers an end-to-end manufacturing service intended to replace skilled human roles in metal part production, aiming to improve lead times, machine utilization, and scalability. Incorporated in 2015, CloudNC seeks to modernize manufacturing by making milling processes more efficient and predictable, supporting industries that rely on precision parts.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.